Anzeige
Mehr »
Samstag, 29.08.2026 - Börsentäglich über 12.000 News
Vom Forschungstrend zum Milliardenmarkt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrModerna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
FrAstraZeneca, Ionis data spark debate about RNA drugs' impact on deadly heart disease
FrThis week in charts: Biotech's rebound is undeniable
FrFDA green lights Priovant drug for rare skin disease
DoMichael Polansky has a new, skin-focused biotech. Don't call it a drug company.
DoNew data could widen use of AstraZeneca, Amgen immune disease drug
DoRevolution pancreatic cancer drug should quickly become a blockbuster, analysts say
MiRevolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
MiSpyre tumbles as immune drug misses mark in rheumatoid arthritis
MiBiohaven trades cash for 'upside' with $795M epilepsy drug deal
MiZepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
DiNew Jazz cancer drug approval could drive blockbuster sales
DiRoche, Eli Lilly get FDA nod for new Alzheimer's blood test
DiWill a 'reset' reignite investment in women's health startups?
DiYoung startups miss out on biotech venture funding rebound, MassBio says
MoSafety concerns spur FDA to again halt testing of Regenxbio gene therapy
MoRoche commits to lean-mass preservation with Hanmi obesity deal
MoFDA extends review of Capricor cell therapy; Pain drug startup to go public
MoCellares, a cell therapy manufacturing specialist, to lay off 100 employees
Mo[Podcast] (Season 2) The Progress Profile: Alzheimer's Research in Focus
MoPharma marketers need a share-of-answer strategy before AI spend
21.08.Shareholder pressures Capricor; Lilly dives deeper into vaccines
21.08.How cost and perception could reshape the GLP-1 market
20.08.Regeneron to challenge Ipsen as FDA clears bone disease drug
20.08.Cancer vaccine win restores Wall Street's faith in Moderna